High Accuracy
cfDNA analysis is structured for high accuracy and a low false-positive rate using advanced NGS technology.
NIPTGEN PLUS
Look to the Future with Confidence
Cell-free fetal DNA testing from maternal blood, performed with Illumina VeriSeq™ NIPT Solution technology.
What is NIPTGEN PLUS?
NIPTGEN PLUS is a reliable, noninvasive prenatal screening test based on next-generation sequencing of cell-free fetal DNA in maternal blood, performed with Illumina VeriSeq™ NIPT Solution.
POWERED BY ILLUMINAIllumina VeriSeq™ NIPT Solution for high accuracy and reliable results.
- 99%+ accuracy
- Low false-positive rate
- Noninvasive and safe
- Performed from maternal blood
- Available from week 10 of pregnancy
- Broad global case experience
- Fast reporting
- Illumina VeriSeq™ infrastructure
Week 10
Available from the 10th week
Available from the 10th week
Early Screening
Typically considered from week 10 of pregnancy; exact timing remains a clinical decision.
Noninvasive
Performed from maternal blood only — no invasive procedure, supporting a safe screening pathway.
Fast Results
Results are shared in a clear, structured report format suited to clinical review.
Screening Scope
Screening scope and test planning are determined by the physician based on clinical evaluation.
Common Chromosomal Aneuploidies
- Down syndrome (Trisomy 21)
- Edwards syndrome (Trisomy 18)
- Patau syndrome (Trisomy 13)
- Klinefelter (47, XXY)
- Triple X (47, XXX)
- Jacob (47, XYY)
- Turner (45, X)
- All chromosomal trisomies/monosomies
20 Microdeletion / Microduplication Syndromes (≥5 MB)
Including DiGeorge, Cri-du-chat, Prader-Willi, Angelman, and other listed syndromes on the clinical panel.
66 Large Deletion / Duplication Syndromes (≥10 MB)
Expanded panel options covering partial monosomy and trisomy regions. Detailed panel selection follows physician evaluation.
Important: NIPTGEN PLUS is a screening test, not a diagnostic test.